GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (NAS:SNSS) » Definitions » Scaled Net Operating Assets

Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Scaled Net Operating Assets : -0.01 (As of Dec. 2020)


View and export this data going back to 2005. Start your Free Trial

What is Sunesis Pharmaceuticals Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sunesis Pharmaceuticals's operating assets for the quarter that ended in Dec. 2020 was $2.84 Mil. Sunesis Pharmaceuticals's operating liabilities for the quarter that ended in Dec. 2020 was $3.04 Mil. Sunesis Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2020 was $28.03 Mil. Therefore, Sunesis Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2020 was -0.01.


Sunesis Pharmaceuticals Scaled Net Operating Assets Historical Data

The historical data trend for Sunesis Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Scaled Net Operating Assets Chart

Sunesis Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.15 -0.07 -0.07 0.31 -0.01

Sunesis Pharmaceuticals Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.13 0.14 -0.05 -0.01

Competitive Comparison of Sunesis Pharmaceuticals's Scaled Net Operating Assets

For the Biotechnology subindustry, Sunesis Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunesis Pharmaceuticals's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunesis Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Sunesis Pharmaceuticals's Scaled Net Operating Assets falls into.



Sunesis Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sunesis Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2020 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2020 )
=(Operating Assets (A: Dec. 2020 )-Operating Liabilities (A: Dec. 2020 ))/Total Assets (A: Dec. 2019 )
=(2.837-3.037)/37.24
=-0.01

where

Operating Assets(A: Dec. 2020 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=23.247 - 20.41
=2.837

Operating Liabilities(A: Dec. 2020 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=3.31 - 0 - 0.273
=3.037

Sunesis Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2020 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2020 )
=(Operating Assets (Q: Dec. 2020 )-Operating Liabilities (Q: Dec. 2020 ))/Total Assets (Q: Sep. 2020 )
=(2.837-3.037)/28.033
=-0.01

where

Operating Assets(Q: Dec. 2020 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=23.247 - 20.41
=2.837

Operating Liabilities(Q: Dec. 2020 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=3.31 - 0 - 0.273
=3.037

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunesis Pharmaceuticals Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.
Executives
Steve Carchedi director 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Nicole Onetto director 58 S SERVICE RD, MELVILLE NY 11747
Henry Ward Wolff director 6701 KAISER DRIVE, FREMONT CA 94555
Steven B Ketchum director 2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
James W Young director
Homer L Pearce director 84 CLIFDEN, ZIONSVILLE IN 46077
Dayton Misfeldt director, officer: See Remarks C/O BAY CITY CAPITAL LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
David C Stump director
Tina Gullotta officer: VP, Finance SUNESIS PHARMACEUTICALS,INC, 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William P. Quinn officer: See Remarks SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Judith A. Fox officer: See Remarks SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Aisling Capital Iv, Lp 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Andrew N Schiff 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Steve Elms 10 percent owner 888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Aisling Capital Partners Iv Llc 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106

Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Headlines

From GuruFocus

Sunesis Pharmaceuticals Provides Corporate Update

By Marketwired Marketwired 07-08-2020